Objectives: The feasibility of providing prolonged and controlled release of the experimental nonnucleoside reverse transcriptase inhibitor TMC120 from a silicone vaginal ring in quantities sufficient to maintain a vaginal concentration offering protection against heterosexual HIV transmission was investigated.
Introduction
Given the devastating effects of the HIV/AIDS epidemic, especially within the developing world, and the continuing difficulties in developing an effective HIV vaccine, there is a clear scientific rationale for developing alternative strategies to prevent HIV infection. The most promising strategy currently being pursued to prevent heterosexually acquired HIV is that of vaginal microbicides. 1, 2 These are chemical substances that, when formulated appropriately and applied to the vagina before intercourse, have the potential to either prevent or reduce the risk of HIV transmission through a number of well-established mechanisms. 1, 2 As of June 2005, 15 HIV microbicide candidates, including the potent experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC120, [3] [4] [5] were undergoing clinical trials. 6 Most of these compounds are being evaluated in conventional semisolid gel formulations designed to provide a single dose of the microbicidal agent, applied immediately before intercourse. The potential for developing controlled release formulations for longterm administration of vaginal microbicides has only recently been considered, 2 and may overcome many of the compliance, acceptability and efficacy issues associated with single-dose, gel-based products. 7 Several in vitro and animal model studies have demonstrated that TMC120 is a potent NNRTI that effectively prevents both cellfree and cell-associated HIV infection at concentrations in the nanomolar range. [3] [4] [5] In an in vitro model using monocyte-derived dendritic cells and autologous CD4+ T cell co-cultures designed to mimic sustained antiretroviral delivery, TMC120 blocked primary infection with monotropic HIV-1 Ba-L at a 0.01 mM concentration and secondary cultures at 0.1 mM. 3 In addition, the low cytotoxicity and high therapeutic index of TMC120 make it an ideal candidate for development as an HIV vaginal microbicide. Currently, microbicidal gel formulations of TMC120 are being tested in Phase 1 trials. The emergence of resistance to NNRTIs is well documented. Although initial studies have demonstrated that TMC120 is active against both wild-type and drug-resistant strains of HIV, the whole issue of resistance, particularly in long-term use as a prophylactic vaginal microbicide, will need to be closely monitored in subsequent clinical investigations.
In this study, we report for the first time the prolonged and controlled release of a lead candidate vaginal microbicide, TMC120, from a silicone elastomer vaginal ring. Vaginal rings have already been commercialized for the sustained release of steroids for hormone replacement therapy (FemringÒ, EstringÒ) and contraception (NuvaringÒ). 7 
Materials and methods

Materials
TMC120 was kindly provided by Tibotec-virco (Mechelen, Belgium). MED6382 medical grade silicone elastomer was supplied by Warner Chilcott UK. Tetrapropyl orthosilicate (95%) and tin(II) 2-ethylhexanoate (95%) were purchased from Sigma-Aldrich (Gillingham, UK). Isopropanol (99.8%) and HPLC-grade acetonitrile were purchased from Riedel-de Haën and ultra-pure water was obtained using an Elga Purelab Maxima system.
Manufacture of core-type silicone vaginal rings loaded with TMC120
Core-type vaginal rings (also known as 'reservoir-type' rings) containing 400 mg of TMC120 in a full-length silicone elastomer core and encapsulated with a non-medicated silicone elastomer sheath layer were manufactured on a laboratory-scale, ring-making machine according to a standard method already described in the literature. 8 The rings had the following characteristics: 5.5 mm core crosssectional diameter; 9.0 mm ring cross-sectional diameter; 55.0 mm overall ring diameter; 10.0 (-0.2) g mean weight of rings.
In vitro release studies
Each TMC120-loaded vaginal ring was suspended in a stoppered 250 mL conical flask containing 200 mL of a 1:1 mixture of isopropanol/water (to ensure sink conditions), and the flasks were placed in an orbital (60 rpm; 32 mm orbital diameter) shaking incubator at 37 C (Sanyo Gallenkamp IOX400.XX2.C). Sampling followed by complete replacement of the release medium was performed every day for the first 14 days and at regular intervals thereafter.
Quantification of release of TMC120 using HPLC analysis
The amount of TMC120 released from the rings was quantified using reversed-phase HPLC with ultraviolet detection (Waters Breeze HPLC system; Phenomenex Synergi 4m Fusion-RP80 column 4.6 mm i.d.·150 mm; temp. 25 C; isocratic mode; mobile phase 1:1 acetonitrile/ 0.01 M pH 2.7 phosphate buffer; flow rate 1.0 mL/min; detection wavelength 290 nm; 10 mL injection volume; TMC120 retention time 2.9 min). A linear calibration plot for TMC120 was obtained over the range 0.1-100 mg/mL (r 2 = 0.999).
Results and discussion
The daily amounts of TMC120 released from the vaginal rings over the initial 14 days of the release study are presented in Figure 1 . The release profile clearly shows a burst phase (days 1 to 2) followed by a linear phase (days 3 to 14). The burst effect has been observed previously in core-type vaginal rings and is a well-understood phenomenon attributed to drug solubility and manufacturing factors. 8 The linear release phase describes a constant daily release ('zero-order' release kinetics) of 140 mg/day resulting from the diffusion-controlled permeation of silicone-solubilized TMC120 molecules from the drug-loaded core, through the non-medicated silicone sheath layer of the ring, and into the surrounding release medium. The linear controlled release profile was maintained over the 71 days of the study, as demonstrated in the cumulative release profile (Figure 2) , providing an average daily release of 136 mg/day (R 2 = 0.9995) as determined by linear regression. The y-intercept value of the line regression equation (c = 0.2444 mg; Figure 2 ) provides a quantitative measure of the magnitude of the initial burst effect. Given that only 2.5% (10 mg) of the total 400 mg TMC120 loading was released over 71 days, and by extrapolating the release profile to longer time periods, it is predicted that this constant daily release rate of TMC120 from a single ring device would easily be maintained for 1 year, and theoretically for up to 4 years (based on 50% total drug release).
Based on upper limits for the volumes of cervicovaginal fluid (8 mL) 9 and semen (8 mL), 10 and assuming that the in vivo release rate of TMC120 from a vaginal ring is similar to the ring-controlled (i.e. diffusion-controlled) release rate observed in vitro (136 mg/day, 5.7 mg/h or 1.7 · 10 -8 mol/h), then the concentrations of TMC120 in the combined fluids within the vagina are calculated to be quickly established within the nanomolar/ micromolar range required to prevent HIV infection (0.1 mM at 10 min, 1.1 mM at 1 h, 13.2 mM at 12 h and 26.4 mM at 24 h after initial ring placement). Of course, the calculations do not take into account the complex dynamics of fluid gain and loss from the vagina, or the possibility of forming tissue depots of TMC120 through continuous use of the ring. However, the results clearly demonstrate the potential for providing long-term and continuous protection against HIV infection in the form of a female-controlled vaginal ring device. Furthermore, the TMC120 release rate from the vaginal ring may be substantially varied through simple modification of the ring dimensions, e.g. varying the TMC120-core length and/or sheath layer thickness. Figure 2 . In vitro cumulative release of TMC120 from silicone, core-type vaginal rings over 71 days.
